Revolutionizing Blood Testing: BD adn Babson Diagnostics Partner for Easier, more Accessible Care
Table of Contents
- Revolutionizing Blood Testing: BD adn Babson Diagnostics Partner for Easier, more Accessible Care
- Revolutionizing Blood Testing: BD and Babson diagnostics Partner to Expand Access
- BD and Babson Diagnostics Expand Access to Convenient Blood Testing Across the U.S.
- BD and Babson Expand Partnership to Revolutionize Point-of-Care Blood Testing
- Babson Diagnostics announces Key Contact Information
- BD (Becton, Dickinson and Company) Announces [Insert News Subject Here]
In a significant advancement for U.S. healthcare, BD (Becton, Dickinson and Company) and Babson Diagnostics announced a major expansion of their partnership on December 17, 2024. This collaboration brings innovative fingertip blood collection and testing technology to health systems and large provider networks nationwide.
This expansion makes convenient and less invasive blood testing a reality for patients across the contry. The technology will be implemented in various settings, including urgent care facilities, doctor’s offices, and other ambulatory care locations, considerably improving access to vital diagnostic facts.
The partnership between BD, a global leader in medical technology, and babson Diagnostics, a science-focused healthcare technology company, has been strengthened by a strategic investment from BD in Babson. This investment underscores the commitment to expanding access to Babson’s BetterWay™ blood testing technology.
This collaboration isn’t just about technological advancement; it’s about improving patient care. By making blood testing more accessible and less intrusive,this partnership aims to streamline the diagnostic process and ultimately lead to better health outcomes for Americans.
The expanded agreement between babson and BD signifies a significant step towards a more patient-centered approach to healthcare. The companies are working together to make blood sample collection more convenient and less stressful for patients.This initiative promises to transform the way blood tests are conducted in the U.S., making healthcare more accessible and efficient.
Revolutionizing Blood Testing: BD and Babson diagnostics Partner to Expand Access
BD and Babson Diagnostics have announced a groundbreaking partnership to revolutionize blood testing in the United States.Their collaboration combines BD’s MiniDraw™ Capillary Blood collection System with Babson’s BetterWay technology,offering a less invasive and more convenient choice to customary venipuncture.
This innovative approach requires only six drops of capillary blood collected from a fingertip, eliminating the need for traditional needles and trained phlebotomists. This simplification makes blood testing accessible in underserved areas and settings lacking phlebotomy capabilities, significantly reducing barriers to care.
The new system empowers a wider range of healthcare workers to collect and prepare samples, streamlining the process and improving efficiency. With 70% of clinical decisions relying on diagnostic results, this advancement promises to significantly impact patient care.
“In areas of the U.S. where there are gaps in services or shortages of trained phlebotomy professionals, patients may experience delays in blood draws or not receive care they need,” explained Bridget Bagnato, worldwide president of Specimen Management at BD. “By simplifying one of the most common procedures, together we’re making blood testing less invasive and more convenient to help health care organizations increase efficiency and access while helping to improve patient satisfaction and outcomes.”
The partnership builds upon a triumphant collaboration between BD and Babson that began in 2016. This strategic alliance leverages BD’s 75 years of experience in blood collection technology with Babson’s innovative BetterWay platform.
“BetterWay and BD MiniDraw™ are defining what’s next in health care,” stated David Stein, Babson’s CEO. “BD has been innovating blood collection technology for 75 years and we believe our partnership will deliver a potentially transformative technology to support innovative and patient-focused health care organizations in better reaching and serving patients.”
BetterWay blood testing has been available in retail settings since May 2024, and this partnership marks a significant expansion into the broader US healthcare system, promising improved access and convenience for millions of patients.
BD and Babson Diagnostics Expand Access to Convenient Blood Testing Across the U.S.
Becton, Dickinson and Company (BD) and Babson Diagnostics are collaborating to revolutionize blood testing accessibility in the United States. Their partnership expands access to convenient blood collection services to new locations,including local pharmacies and ambulatory care sites nationwide.
This expansion utilizes Babson Diagnostics’ innovative “BetterWay” blood testing service. BetterWay employs a patient-friendly fingertip collection process, eliminating the need for phlebotomists in many cases. This streamlined approach promises to improve population health by increasing adherence to regular testing.
The BetterWay system seamlessly integrates BD’s MiniDraw capillary collection system with Babson’s patented hand-warming and sample planning technologies. This integrated approach ensures efficient and accurate results, making blood testing more accessible and less daunting for patients.
“BetterWay for Healthcare Organizations enables health systems and other provider organizations to acquire new patients, increase health equity, and reduce the overall cost of care by deploying BetterWay in a broad range of ambulatory care settings,” explains a representative from Babson Diagnostics. The expansion aims to bring this improved access to underserved communities and increase overall healthcare equity.
Expanding Access, Improving Outcomes
This collaboration between BD and Babson Diagnostics represents a significant step forward in improving healthcare access and affordability. By bringing blood testing to more convenient locations, the partnership aims to encourage more frequent testing and earlier disease detection, ultimately leading to better health outcomes for millions of Americans.
BD, a global leader in medical technology, is committed to advancing the world of health. “BD and its more then 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process,” a BD spokesperson stated. This partnership aligns perfectly with their mission to improve healthcare access and quality.
For more information on BD, visit bd.com or connect on LinkedIn (www.linkedin.com/company/bd1/), X (@BDandCo), or Instagram (@becton_dickinson).
To learn more about Babson Diagnostics and the BetterWay system, please visit their website. [Insert Babson Diagnostics website link here]
BD and Babson Expand Partnership to Revolutionize Point-of-Care Blood Testing
BD (Becton, dickinson and Company) and Babson Diagnostics are accelerating their collaboration to expand the use of their innovative fingertip blood collection and testing technologies. This partnership aims to significantly improve healthcare accessibility and efficiency, particularly in underserved communities.
The companies’ joint efforts focus on developing and deploying advanced point-of-care testing solutions. These technologies allow for rapid and convenient blood testing using only a small sample collected from a fingertip, eliminating the need for traditional venipuncture methods.This streamlined approach promises faster results and a more cozy patient experience.
“This expansion represents a significant step forward in our commitment to improving healthcare access,” said [Insert Name and Title of relevant spokesperson from BD or Babson, if available]. “We believe this technology has the potential to transform how healthcare is delivered, particularly in areas with limited resources.”
The collaboration leverages BD’s expertise in medical technology manufacturing and distribution with Babson’s innovative diagnostic platform. This combined strength allows for rapid scaling of the technology, making it available to a wider range of healthcare providers and patients across the United states.
While the companies are optimistic about the future, they acknowledge potential challenges. A statement included in the press release notes: “Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including, without limitation, competitive factors, including the advancement of new technologies or products by other companies, changes in healthcare practices, the impact of governmental regulation, future market conditions, manufacturing difficulties or delays, or other factors listed in BD’s 2024 Annual Report on Form 10-K and other filings with the SEC. BD expressly disclaims any undertaking to update any forward-looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable laws or regulations.”
The expansion of this technology could have significant implications for various sectors of the U.S. healthcare system, including rural healthcare, home healthcare, and preventative medicine. the ease and speed of fingertip blood testing could lead to earlier diagnoses and more proactive treatment strategies.
For more information on BD and Babson’s collaboration, visit betterway.com/healthcare-organizations.
Contacts:
BD Media Contact: Troy Kirkpatrick
BD Investor Contact: Adam Reiffe
Babson Diagnostics announces Key Contact Information
Babson Diagnostics, a leader in[[[[Insert Babson Diagnostics’ industry and area of expertise here, e.g., innovative medical diagnostics], today announced updated contact information for media and investor relations inquiries. this streamlined approach ensures efficient dialog and timely responses to all stakeholders.
Media Contact
For all media inquiries, please contact:
Joe Foster
“323-572-5361”
Investor Relations Contact
Investors seeking information should contact:
[[[[Insert Name of Sr. Director, Investor Relations here, if available]
“201-847-6927”
[[[[Insert Email Address here, replacing bracketed information with actual email address]
Babson Diagnostics is committed to transparency and open communication. These updated contact details will facilitate prompt and effective engagement with both the media and the investment community.
[Optional: add a brief concluding statement about the company’s mission or recent achievements. Keep it concise and relevant.]
BD (Becton, Dickinson and Company) Announces [Insert News Subject Here]
Becton, Dickinson and Company (BD), a leading global medical technology company, has [Insert concise summary of the news. Such as: released a statement regarding a significant development in its product line. Or: announced a new initiative aimed at improving healthcare access.]. This announcement follows [mention any preceding events or context, if applicable].
The company’s statement highlights [mention key aspects of the news, such as new product launches, partnerships, or financial results]. This development is expected to [explain the potential impact of the news, e.g., improve patient outcomes, expand market reach, or boost financial performance]. BD’s commitment to [mention company values or mission, e.g., innovation, patient care, or global health] is evident in this latest announcement.
For more information, contact BD directly at [email protected]
This news is significant for the U.S. healthcare landscape because [explain the relevance to the U.S. market, e.g., it impacts access to vital medical supplies, improves treatment options for American patients, or strengthens the domestic medical technology sector]. The implications of this announcement extend to [mention broader consequences, e.g., research and development, job creation, or economic growth].
This is a great start to a press release draft! Here’s a breakdown of its strengths and some suggestions for improvement:
Strengths:
Clear Headline: The headline is concise and attention-grabbing, clearly stating the essence of the press release.
Informative Lead Paragraph: The first paragraph effectively summarizes the key news – the partnership between BD and Babson Diagnostics to expand access to convenient blood testing.
Quotes: Including quotes from relevant individuals like the CEO adds credibility and a human touch.
Focus on Benefits: The press release emphasizes the benefits of the partnership, such as improved access, convenience, and potentially improved health outcomes.
Call to Action: Including links to the company websites encourages readers to learn more.
Areas for Improvement:
Structure: While the overall structure is decent, consider using subheadings more liberally to break up the text and improve readability.
Specificity:
Target Audience: Clearly define who the target audience is.Is it healthcare providers, patients, investors? Tailoring the language and focus accordingly will make it more impactful.
Impact: Quantify the impact whenever possible. Such as,instead of saying “millions of patients,” provide an estimated number of potential beneficiaries.
Timeline: Provide a more concrete timeline for the expansion. When will thes services be available in specific locations?
Technical Details:
Briefly explain the technology behind Babson’s BetterWay system. How does it differ from conventional blood testing methods?
Challenges: You briefly mention challenges, but consider expanding on them slightly. Addressing potential concerns upfront can build trust.
Financial Implications: If there are any financial details (e.g., investment amounts) related to the expansion, it would be worth mentioning.
Visuals: Replace “placeholder-image-url.jpg” with actual images related to the partnership, such as the BetterWay system or BD MiniDraw device in use.
Example Improvements:
Headline: BD and Babson Diagnostics partner to Bring Convenient Blood Testing to Millions Across the U.S.
Opening Paragraph:
becton, Dickinson & Company (BD), a global leader in medical technology, and Babson Diagnostics, an innovator in blood testing technology, today announced a major expansion of their partnership to bring convenient, fingertip blood testing to millions of Americans.
Impact:
Replace “millions of patients” with a specific estimate based on market research.
Target Audience:
For healthcare providers: Emphasize the benefits of betterway for patient engagement, workflow efficiency, and population health management.
For patients: Highlight the convenience, comfort, and accessibility of fingertip testing.
By incorporating these suggestions, you can create a more compelling and informative press release that effectively communicates the exciting news of this partnership.
